Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Farmers Insurance
Queensland Health

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,916,941

« Back to Dashboard

Which drugs does patent 6,916,941 protect, and when does it expire?

Patent 6,916,941 protects LEXAPRO and is included in one NDA. There have been two Paragraph IV challenges on Lexapro.

Protection for LEXAPRO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 6,916,941

Title: Crystalline composition containing escitalopram
Abstract:Crystalline particles of escitalopram oxalate with a particle size of at least 40 .mu.m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.
Inventor(s): Christensen; Troels Volsgaard (Holb.ae butted.k, DK), Liljegren; Ken (V.ae butted.rl.o slashed.se, DK), Elema; Michiel Onne (K.o slashed.bnhavn .O slashed., DK), Andresen; Lene (R.o slashed.dovre, DK), Mahashabde; Shashank (Kendall Park, NJ), Assenza; Sebastian P. (Fort Salonga, NY)
Assignee: H. Lundbeck A/S (Valby-Copenhagen, DK)
Application Number:10/403,453
Patent Claim Types:
see list of patent claims
Compound; Use; Formulation; Dosage form; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Forest LabsLEXAPROescitalopram oxalateTABLET;ORAL021323-001Aug 14, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Forest LabsLEXAPROescitalopram oxalateTABLET;ORAL021323-002Aug 14, 2002ABRXYesNo► Subscribe► SubscribeY► Subscribe
Forest LabsLEXAPROescitalopram oxalateTABLET;ORAL021323-003Aug 14, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,916,941

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
DenmarkPA 2001 01164Jul 31, 2001

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
US Department of Justice
US Army
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: